Safely and immunogenicity of modified vaccinia ankara (ACAM3000): Effect of dose and route of administration

Journal of Infectious Diseases

Volumn 201, Issue 9, 2010, Pages 1361-1370

  Wilck, Marissa B ^a,e   Seaman, Michael S ^b,e   Baden, Lindsey R ^a,e   Walsh, Stephen R ^c,e   Grandpre, Lauren E ^b   Devoy, Colleen ^b   Giri, Ayush ^b   Kleinjan, Jane A ^a   Noble, Lizanne C ^a   Stevenson, Kristen E ^d   Kim, Haesook T ^d   Dolin, Raphael ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAM 3000; GAMMA INTERFERON; MODIFIED VACCINIA ANKARA; PLACEBO; UNCLASSIFIED DRUG; VACCINIA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VIRUS ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE CULTURE; VACCINIA; ADOLESCENT; ANTIBODY PRODUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINIA VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA VIRUS; YOUNG ADULT;

EID: 77950934570     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651561     Document Type: Article

References (34)

1. Declaration of global eradication of smallpox. Wkly Epidemiol Rec 1980;55:145-152.
2. Fenner F, Henderson D, Arita I, Jezek Z. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988:307.
3. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201-1208.
4. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-309.
5. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [in German; author's translation], Zentralbl Bakteriol B 1978;167:375-390.
6. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998; 79(Pt 5):1159-1167. (Pubitemid 28203857)
7. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997; 238:198-211. (Pubitemid 28218138)
8. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79(Pt 2):347-352. (Pubitemid 28048439)
9. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244:365-396. (Pubitemid 28384101)
10. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991; 72(Pt 5):1031-1038.
11. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. JAMA 1985;254:3203-3206.
12. Sabchareon A, Chantavanich P, Pasuralertsakul S, et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998;17:1001-1007.
13. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-2301. (Pubitemid 39552745)
14. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-2294. (Pubitemid 39552744)
15. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007;25:6755-6763. (Pubitemid 47332726)
16. Grandpre LE, Duke-Cohan JS, Ewald BA, et al. Immunogenicity of recombinant modified vaccinia Ankara following a single or multidose vaccine regimen in rhesus monkeys. Vaccine 2009;27:1549-1556.
17. Zhu Y, Yin J. A quantitative comet assay: imaging and analysis of virus plaques formed with a liquid overlay. J Virol Methods 2007; 139: 100-102. (Pubitemid 44854222)
18. + cytotoxic T lymphocytes and interferonγ-producing T cells after smallpox vaccination. J Infect Dis 2002; 185: 1657-1659.
19. Frey SE, Newman FK, Cruz J, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002;346:1275-1280.
20. Walsh SR, Gillis J, Peters B, et al. Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. Vaccine 2009;27:4990-5000.
21. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-172. (Pubitemid 34132882)
22. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24:2065-2070. (Pubitemid 43255148)
23. Frey SE, Newman. FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007;25:8562-8573.
24. Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007; 25: 1513-1525.
25. Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009; 90(Pt. 8):1962-1966.
26. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83:2915-2931. (Pubitemid 36054337)
27. Kaufman DR, Goudsmit J, Holterman L, et al. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol 2008;82:6829-6837. (Pubitemid 351977704)
28. Heraud JM, Edghill-Smith Y, Ayala V, et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 2006; 177:2552-2564. (Pubitemid 44201014)
29. Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004; 78: 4433-4443. (Pubitemid 38501063)
30. Berhanu A, Wilson. RL, Kirkwood-Watts DL, et al. Vaccination of BALB/ c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008; 82:3517-3529.
31. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005;79:13454-13462. (Pubitemid 41508158)
32. Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008; 89:2992-2997.
33. Davies DH, McCausland MM, Valdez C, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005; 79: 11724-11733. (Pubitemid 41279291)
34. Nelson GE, Sisler JR, Chandran D, Moss B. Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 2008;380:394-1101